3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
545
Lung Neoplasms
240
Small Cell Lung Carcinoma
106
Mesothelioma, Malignant
57
Adenocarcinoma of Lung
41
Mesothelioma
35
Neoplasms
27
Neoplasm Metastasis
25
Colorectal Neoplasms
22
Carcinoma
17
Squamous Cell Carcinoma of Head and Neck
15
Ovarian Neoplasms
15
Adenocarcinoma, Bronchiolo-Alveolar
14
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Stomach Neoplasms
12
Pancreatic Neoplasms
12
Non-Squamous Non-Small Cell Lung Cancer
12
Head and Neck Neoplasms
12
Pleural Effusion, Malignant
8
Melanoma
8
Breast Neoplasms
8
Sarcoma
7
Extensive Stage Small Cell Lung Cancer
7
Triple Negative Breast Neoplasms
6
Thymoma
6
Solitary Fibrous Tumor, Pleural
6
NSCLC
6
Endometrial Neoplasms
6
Drug-Related Side Effects and Adverse Reactions
6
Colonic Neoplasms
6
Interventions
Vinorelbine
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metatropic dwarfism
×
Cisplatin
×
Thoracic
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts